Background-Collateral damage to the vagal nerve and the upper gastrointestinal (UGI) system during atrial fibrillation ablation has not been systematically evaluated. Methods and Results-We performed a prospective, observational study assessing the effect of atrial fibrillation ablation on the function of the vagus nerve/UGI system. All patients underwent esophageal manometry, gastric emptying study, and sham-feeding test (corresponding to esophageal, gastric, and small intestinal function evaluation, respectively) before ablation (baseline) and subsequently at 24 hours, 90 days, and 180 days after the procedure. In addition, UGI symptom assessment using the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) questionnaire was performed at baseline and during each of the subsequent evaluations. Of the 27 patients enrolled in the study, 9 (33%) patients had abnormal UGI function at baseline; defined as at least one of the 3 abnormal tests. At 24 hours after the radiofrequency catheter ablation, 20 (74%) patients had at least 1 new abnormality on the UGI function tests (P<0.001). New onset esophageal dysmotility, delayed gastric emptying time, and abnormal sham-feeding tests were observed in 13 (48%), 13 (48%), and 9 (33%) patients, respectively. Mean PAGI-SYM scores increased from 7.78±6.6 at baseline to 15.56±13.4 (P=0.002) at 24 hours. New onset abnormalities persisted in 9 (33%) patients at 3 months and normalized in all patients at 6 months. Conclusions-Atrial fibrillation ablation results in functional impairment of the UGI system, including the esophagus, stomach, and small intestine. This impairment is transient and is probably mediated by the injury to the components of the vagal nerve. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique Identifier: NCT01396356.
A trial fibrillation (AF) is the most common arrhythmia with a current estimated prevalence exceeding 5 millions in the United States. 1 In addition, this number is expected to grow more than double in the next 20 years. 1 Radiofrequency catheter ablation (RFA) for AF is the standard of care for drug-refractory symptomatic AF. 2 It is being increasingly performed and is also the first line therapy in certain patient populations. 2 AF ablation is a complex and technically challenging procedure requiring extensive RFA in the left atrium (LA). Collateral damage to the neighboring structures, including the upper gastrointestinal (UGI) system, during AF ablation have been well reported. UGI complications are some of the most dreaded complications of AF ablation. Some of the reported UGI complications resulting from AF ablation include atrioesophageal fistulae, esophageal mucosal ulcerations with or without bleeding, gastroesophageal reflux, pyloric spasm, and gastric hypomotility. [3] [4] [5] [6] [7] [8] [9] [10] [11] The exact mechanism of these injuries is not known; however, injury to the vagus nerve (VN) and its components are proposed to be one of the major players in many of these complications. 5, 10 The VN because of its close proximity to the posterior wall of the LA is susceptible to the thermal injury from RFA. Despite the significance, prospective studies designed to understand the effect of AF ablation on the various functional components of VN are lacking. 12 The AF-GUT study is the first, prospective study designed to evaluate the effect of AF ablation on the functional abnormalities of the UGI system resulting from VN injury. study was approved by the hospitals institutional review board, and all patients were appropriately consented (NCT01396356).
Inclusion and Exclusion Criteria
All consecutive patients undergoing AF ablation for drug-refractory symptomatic AF in 2012 at our center were screened for the study. Details of the inclusion and exclusion criteria are shown in Table I in the Data Supplement. In brief, patients with no previous cardiac surgery undergoing AF ablation for the first time with no previous documented/suspected UGI pathology were offered to participate in the study. Informed consent was obtained from all the patients, which included undergoing repeat testing for VN/UGI system function.
VN Functional Assessment
The functional integrity of VN components for various segments of the UGI system was assessed independently with specific tests. The esophageal, gastric, and the small intestinal function were assessed using esophageal manometry (EM), gastric emptying scan (GES), and sham-feeding test (SFT), respectively. Baseline assessment was performed 1 to 7 days before the procedure. Repeat assessment with all the 3 tests were performed for all patients at 24 hours, 90 days, and 180 days after the RFA procedure. In addition, all patients answered the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) questionnaire at each of the above assessment times. PAGI-SYM questionnaire is a well-accepted, validated tool to reliably quantify symptom burden in patients with UGI disorders 13 ( Figure I in the Data Supplement).
AF Ablation and Imaging
All patients underwent preablation computed tomographic scan of the heart, which was used for the anatomic measurements. Volumetric analysis was used to calculate the pericardial fat volume. The maximum thickness of the pericardial fat around the atria is used for measuring periatrial fat. The details of AF ablation procedure have been described elsewhere. 14, 15 In brief, all patients underwent double transeptal puncture using intracardiac echocardiography. In patients with paroxysmal AF, the procedural end point was pulmonary vein isolation using a roving-lasso technique. In patients with persistent AF, additional substrate modification guided by complex fractionated electrograms was also performed. Extensive posterior wall ablation was not performed. Posterior wall complex fractionated atrial electrogram ablation was performed at the operator's discretion. The number of complex fractionated atrial electrogram lesions in posterior wall ranged between 3 and 12 lesions. In patients with atrial flutter, additional mapping and ablation were performed at the discretion of the operator. A 3.5-mm irrigated ablation catheter was used with a flow rate of 30 mL/min. All ablation lesions were at or above 30 Watts. Radiofrequency energy output was titrated to 40 and 30 Watts along the anterior and posterior walls/segments of the atria, respectively. Luminal esophageal temperature (LET) was monitored using a single-sensor system (Temp Sensor, Esophageal, 9FR, Physio-control), and its position was adjusted to measure the esophageal temperature closest to the tip of the ablation catheter. An increase in the LET >39°C was documented, and radiofrequency application was stopped till the temperature reaches <38°C.
Esophageal Manometry
EM is a diagnostic procedure used for the assessment of upper and lower esophageal sphincter pressures along with the peristalsis of the esophageal body, including contraction amplitude. 16 After fasting for at least 6 hours, the upper and lower esophageal sphincter pressures and motility pattern of the esophagus were monitored and recorded. The test was considered abnormal if there was one of the following; a decrease in upper and lower esophageal sphincter pressures, abnormal motility pattern, loss of peristalsis, >20% simultaneous contractions, or nutcracker esophagus.
Gastric Emptying Scan
GES is a nuclear study performed to evaluate the gastric motility and emptying. 17 After an overnight fast, patients were asked to consume a freshly prepared radionuclide meal in the morning. Anterior and posterior scintigraphic images of the stomach were obtained within 1 minute of completion of the meal and again at 60, 120, 180, and 240 minutes. Abnormal gastric emptying was assessed using the 240-minute images. Mild, moderate, and severe gastroparesis were defined as a 240-minute gastric retention of 11% to 15%, 16% to 35%, and >35%, respectively (Figure II in the Data Supplement).
Sham-Feeding Test
SFT is a noninvasive test for assessing VN-mediated secretory function of the pancreas mediated through gastric receptors. Pancreatic polypeptide secretion is biphasic after a meal, the initial component is mediated by the VN, and the later component is mediated by neurohormonal and enteropancreatic mechanisms. 18 After an overnight fast, 2 baseline blood samples for pancreatic polypeptide were collected. Patients were then asked to chew and spit out a meal. Blood samples of glucose and pancreatic polypeptide were collected at 10-minute intervals for 30 minutes after chewing and spitting out the meal. Pancreatic polypeptide level elevation <50% from baseline after sham-feeding was considered as abnormal.
PAGI-SYM UGI Symptom Questionnaire
This questionnaire is a well-accepted and validated tool to evaluate UGI symptoms. 13 It includes a series of questions (20-item) relating to multiple UGI symptoms. Patients rate their symptoms on a subjective scale of 0 to 5, where 0 represents no symptoms and 5 represents the worst severity of that symptom ( Figure I in the Data Supplement).
Follow-Up
We used a standard protocol for follow-up. All patients undergo 2-month nonlooping event monitor immediately post ablation. At 6-month follow-up, we perform additional 1-week continuous looping monitor. At 1 year, we again do a 2-week nonlooping event monitor. In addition, patients underwent 12-lead ECG at 1-month, 2-month, 6-month, and 1-year follow-up. If patients develop symptoms, additional monitoring was performed.
WHAT IS KNOWN
• Gastrointestinal complications of atrial fibrillation ablation include rare atrioesophageal fistulae, esophageal mucosal ulcerations with or without bleeding, gastroesophageal reflux, pyloric spasm, and gastric hypomotility.
• The exact mechanism of these complications is not known; however, injury to the vagus nerve and its components are proposed to be a significant factor.
WHAT THE STUDY ADDS
• Evaluations before and after atrial fibrillation ablation show some degree of upper gastrointestinal dysfunction consistent with vagal nerve injury in the majority of patients.
• These abnormalities are transient but can last >3 months.
• Often the abnormality is not symptomatic but can be exposed by functional testing.
Data Collection and Statistical Analysis
Demographic variables, past medical history, medication history, procedural variables, UGI function assessment variables, and PAGI-SYM scores were collected prospectively and assessed. Continuous variables are expressed as mean±SD and categorical variables as proportions. Univariable analyses were performed using χ 2 test (with or without Fisher exact correction) for categorical variables and Student t test for continuous variables. Paired tests were performed when appropriate. McNemar test was used for evaluating paired samples. Preablation and postablation EM, GES, SFT, and PAGI-SYM scores were compared using paired t test. Statistical analysis was considered significant at P values <0.05. Statistical analysis was performed using SAS 9.1 (SAS Institute Inc, Cary, NC).
Results
Of the 250 patients who underwent AF ablation in 2012, 50 patients qualified for the study based on the inclusion and exclusion criteria. Of these, 27 patients consented for the study and were enrolled. Baseline characteristics of the study sample are listed in Table 1 . The mean age of the population was 60±12 years with 17 (63%) patients being men. Median AF duration before the procedure was 24 months. The mean LA size was 4.3±0.7 cm, the and mean left ventricular ejection fraction was 56±8. The mean distance from posterior LA wall to the esophagus as measured on the computed tomographic scan was 2±2.3 mm.
The procedure was performed under general anesthesia in 6 (22%) patients, and the rest under moderate sedation. All patients underwent pulmonary vein isolation. In addition, 19 (70%) patients underwent additional ablation in the form of complex fractionated electrogram ablation or linear ablations. The mean ablation time was 36±24 minutes. At 6-month follow-up, 21 (79%) patients were in sinus rhythm off antiarrhythmics after 1 ablation and 24 (89%) patients were in sinus rhythm off antiarrhythmics after ≥1 procedures. (Table 1) .
At baseline, 9 (33%) patients had abnormal UGI function, as defined as at least 1 abnormal test (Figure) . EM and SFT were abnormal in 22% (6) and 11% (3) of patients, respectively. One patient with abnormal EM was confirmed to have nutcracker esophagus. Post RFA at 24 hours, 20 (74%) patients were noted to have a new onset abnormal UGI function (P<0.001 when compared with baseline). New onset esophageal dysmotility, delayed gastric emptying, and abnormal SFTs were observed in 13 (48%), 13 (48%), and 9 (33%) patients, respectively (P<0.05 for all comparisons with baseline). Of the ones with new onset abnormality, 9 (33%) had 1 abnormality, 6 (22%) had 2 abnormalities, and 5 (19%) had abnormalities of all 3 tests at 24 hours post RFA. The mean PAGI-SYM scores increased from 7.8±6.6 at baseline to 15.6±13.4 (P=0.002) at 24 hours post RFA. Patients who had ≥2 new abnormalities at 24 hours had a higher PAGI-SYM scores than those who had 1 or no new abnormality (13.45±12.9 versus 3.87±9.4; P=0.035; Table 2 ).
All the subjects underwent repeat testing at 90 days post RFA. Ten (37%) patients had at least 1 abnormal test; of which, 9 (33%) were patients with no abnormalities at baseline. In general, the number of patients with an UGI abnormality decreased from 24 hours post RFA to 90 days post RFA (13/48% to 8/30%, 13/48% to 4/15%, and 12/44% to 6/22% for abnormal EM, GES, and SFT tests respectively; P<0.05 for all). Interestingly, 1 (3%), 2 (7%), and 4 (15%) patients developed new onset abnormalities in EM, GES, and SFT tests, respectively, between 24 hours and 90 days post RFA. The mean PAGI-SYM score at 3 months of follow-up was 8.33±9.5 (P=0.706 compared with baseline). At 6 months of follow-up, all the patients who developed new abnormal UGI function studies after RFA were found to have normal functional tests. Esophageal dysmotility and abnormal SFTs were present in 1 (4%) patient each. Both of these patients had abnormal tests at baseline. None of the patients died during follow-up, and none developed atrioesophageal fistula.
We also evaluated whether patient characteristics, anatomic or intraprocedural variables, predicted the occurrence of an abnormality on the UGI functional testing in univariable analyses. Age, type of AF, LA size, distance between LA and esophagus, periatrial fat, pericardial fat, use of general anesthesia for the procedure, duration of ablation, ablation beyond pulmonary vein isolation, posterior wall ablation time, or LET Diabetes mellitus (%) 2 (7) Hyperlipidemia (%) 9 (33) Heart failure (%) 1 (4) Obesity (%) 3 (11) Previous stroke (%) 1 (4) Obstructive sleep apnea (%) 4 (15) Hiatal hernia (%) 0
Thyroid disease (%) 5 (19) Chronic obstructive pulmonary disease (%) 1 (4) Asthma ( >39°C did not predict the development of an UGI abnormality at 24 hours or 90 days post RFA.
Discussion
In our prospective observational study, we found that AF ablation results in VN injury in a majority of patients resulting in UGI dysfunction. These abnormalities are transient but can last >3 months in many patients. Often, the manifestations seem to be subclinical and are picked up by functional testing. This is the first study-to-date to systematically evaluate VN function post AF ablation. AF ablation can result in collateral damage involving multiple structures neighboring the heart. The mechanisms of these injuries are probably multifactorial. Some immediately neighboring structures sustain a reasonably well-described direct thermal injury (eg, phrenic nerve). However, many other structures probably sustain a combination of direct thermal, microvascular, and regional nervous system injuries (eg, UGI system). Some of the well-identified UGI system complications, including atrioesophageal fistulae, esophageal ulcerations, gastroesophageal reflux, acute pyloric spasm, and gastric hypomotility, are at least partially a consequence of VN injury. [3] [4] [5] [6] [7] [8] [9] [10] [11] Because the consequences of UGI injury can be catastrophic, the importance of understanding the effect of AF ablation on VN injury cannot be overstated.
VN and its branches are anatomically closely related to the posterior wall of the LA and the pulmonary veins that are the principal sites of RFA in AF. 19, 20 The VN and its branches innervate most of the UGI system. The right and left VN descend alongside the esophagus into the abdomen, and their course in the posterior mediastinum is variable. The right and left vagal trunks may form a plexus anteriorly (34%), posteriorly (19%), and both anteriorly and posteriorly (44%) or may course independently without forming any plexus (3%). 21 The parasympathetic efferents from the anterior and posterior esophageal plexuses supply the upper and lower esophageal sphincter and also synapse with the intrinsic myenteric plexus of the esophagus and thereby regulate the sphincters and peristalsis of the esophagus. 22, 23 Branches from the anterior and posterior vagal trunk (formed from the periesophageal plexi) supply the vagal efferents to the stomach and the pyloric sphincter. 24 The posterior vagal trunk forms the celiac plexus, branches of which supply the pancreas. 24 Symptomatic VN injury identified by significant UGI hypomotility symptoms has been reported in 1% to 2% of the patients undergoing AF ablation. 5, 10 However, the studies were limited by their retrospective nature and lack of routine screening with objective diagnostic tests. In this study, all patients underwent rigorous VN function assessment at baseline and multiple times post procedure. Accordingly, we identified a much higher rate (74%) of VN injury/UGI dysfunction at 24 hours post RFA. Moreover, 33% had the abnormality persistence for 3 months post RFA. Abnormalities on the UGI function tests correlated with worse PAGI-SYM questionnaire supporting the clinical importance of the abnormal findings. In previous studies, most common presenting symptoms of VN injury were symptoms of UGI dysmotility. This is in line with our findings; 48% of our patients had findings of UGI dysmotility (abnormal EM or abnormal GES). The majority of the subjects with abnormal GES or SFT also had esophageal dysmotility suggesting injury to the VN at the level of esophagus, posterior to the LA, where it forms plexi.
VN injury can be a result of a direct neuronal injury from RFA as evidenced by decrease gastric myoelectricity. 25, 26 It can also be a result of plexi compression from edema resulting from an RFA-induced inflammatory response of the neighboring mediastinal structures (indirect consequence of RFA). 8 Microhematomas from vascular injury during RFA may also cause the same effect on these plexi. 27 It should also be noted that some of UGI dysfunction can be because of direct injury to the intrinsic (myentric) plexi of the esophagus without affecting the VN, through the similar pathological mechanisms. 28 In a recent study by Singh et al, 29 there was no correlation between LET and esophageal ulcerations or ablation energy and LET. Our findings were consistent with their study, and we did not find any association between LET and VN injury. LET is measured from the esophageal lumen, and periesophageal VN plexi are external to the esophagus. LET may not be a true reflection of the periesophageal temperatures, and temperature rise may be higher at these sites than inside the lumen where the LET probe is positioned. Furthermore, during our study, the power of radiofrequency during ablation of posterior segments of the LA was limited to 30 W only. Despite monitoring the LET and limiting power while ablating the posterior atrial segments, the majority of our subjects had VN injury. The LA to esophagus distance, periatrial fat pad, and thickness of pericardial fat layer were not different in subjects with and without GI dysmotility; therefore, the individual susceptibility to VN damage during RFA may be difficult to predict.
Clinical symptoms seem to be more evident when >2 components of vagal innervation to the UGI are affected. Interestingly, most of the VN injury-related physiological abnormalities seem to be subclinical and tend to resolve without any intervention. Perhaps, structural damage to the periatrial structures may be inevitable despite all the precautionary measures used. Anatomic orientation of the nerve plexus specific to individual patients is probably what determines the type and severity of neuronal injury and associated physiological and structural changes. Those patients with robust anterior plexi behind the LA may perhaps sustain maximal injury, and those with only posterior plexi behind the esophagus may completely escape vagal injury. Monitoring of LET, periprocedural imaging with computed tomography, MRI or intracardiac echocardiography, modulation of power and duration of radiofrequency energy during ablation and mechanical esophageal displacement have been suggested as possible ways to decrease injury to the esophagus. [29] [30] [31] [32] [33] [34] [35] [36] [37] However, their roles in preventing VN injury during RFA have not been systematically studied. Further studies are therefore necessary to identify methods to safely perform AF ablation without damaging the VN.
Limitations and Clinical Implications
This was a single-center study and included a small sample size. Structural abnormalities of the UGI tract using endoscopy were not assessed and therefore could not be correlated with the functional abnormalities. We assessed only the efferent functions of the VN on UGI tract. There is no sophisticated imaging technology available at this time to delineate the course of VN and its branches. Future studies looking at the correlation between the anatomic course of the VN and functional impairment of UGI system after AF ablation will be important to better understand our study findings.
Conclusions
UGI functional abnormalities after AF ablation, as detected by functional studies, are common, occurring in 74% of the patients. These abnormalities are transient and resolved within 3 to 6 months.
